BACKGROUND: Multivalent influenza vaccine products provide protection against influenza A(H1N1)pdm09, A(H3N2), and B lineage viruses. The 2018-2019 influenza season in the United States included prolonged circulation of A(H1N1)pdm09 viruses well-matched to the vaccine strain and A(H3N2) viruses, the majority of which were mismatched to the vaccine. We estimated the number of vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for the season. METHODS: We used a mathematical model and Monte Carlo algorithm to estimate numbers and 95% uncertainty intervals (UIs) of influenza-associated outcomes prevented by vaccination in the United States. The model incorporated age-specific estimates of national 2018-2019 influenza vaccine coverage, influenza virus-specific vaccine effectiveness from the US Influenza Vaccine Effectiveness Network, and disease burden estimated from population-based rates of influenza-associated hospitalizations through the Influenza Hospitalization Surveillance Network. RESULTS: Influenza vaccination prevented an estimated 4.4 million (95%UI, 3.4 million-7.1 million) illnesses, 2.3 million (95%UI, 1.8 million-3.8 million) medical visits, 58 000 (95%UI, 30 000-156 000) hospitalizations, and 3500 (95%UI, 1000-13 000) deaths due to influenza viruses during the US 2018-2019 influenza season. Vaccination prevented 14% of projected hospitalizations associated with A(H1N1)pdm09 overall and 43% among children aged 6 months-4 years. CONCLUSIONS: Influenza vaccination averted substantial influenza-associated disease including hospitalizations and deaths in the United States, primarily due to effectiveness against A(H1N1)pdm09. Our findings underscore the value of influenza vaccination, highlighting that vaccines measurably decrease illness and associated healthcare utilization even in a season in which a vaccine component does not match to a circulating virus. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Multivalent influenza vaccine products provide protection against influenza A(H1N1)pdm09, A(H3N2), and B lineage viruses. The 2018-2019 influenza season in the United States included prolonged circulation of A(H1N1)pdm09 viruses well-matched to the vaccine strain and A(H3N2) viruses, the majority of which were mismatched to the vaccine. We estimated the number of vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for the season. METHODS: We used a mathematical model and Monte Carlo algorithm to estimate numbers and 95% uncertainty intervals (UIs) of influenza-associated outcomes prevented by vaccination in the United States. The model incorporated age-specific estimates of national 2018-2019 influenza vaccine coverage, influenza virus-specific vaccine effectiveness from the US Influenza Vaccine Effectiveness Network, and disease burden estimated from population-based rates of influenza-associated hospitalizations through the Influenza Hospitalization Surveillance Network. RESULTS: Influenza vaccination prevented an estimated 4.4 million (95%UI, 3.4 million-7.1 million) illnesses, 2.3 million (95%UI, 1.8 million-3.8 million) medical visits, 58 000 (95%UI, 30 000-156 000) hospitalizations, and 3500 (95%UI, 1000-13 000) deaths due to influenza viruses during the US 2018-2019 influenza season. Vaccination prevented 14% of projected hospitalizations associated with A(H1N1)pdm09 overall and 43% among children aged 6 months-4 years. CONCLUSIONS: Influenza vaccination averted substantial influenza-associated disease including hospitalizations and deaths in the United States, primarily due to effectiveness against A(H1N1)pdm09. Our findings underscore the value of influenza vaccination, highlighting that vaccines measurably decrease illness and associated healthcare utilization even in a season in which a vaccine component does not match to a circulating virus. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Nimalan Arinaminpathy; Inkyu Kevin Kim; Paul Gargiullo; Michael Haber; Ivo M Foppa; Manoj Gambhir; Joseph Bresee Journal: Am J Epidemiol Date: 2017-07-01 Impact factor: 4.897
Authors: Jeffrey C Kwong; Kevin L Schwartz; Michael A Campitelli; Hannah Chung; Natasha S Crowcroft; Timothy Karnauchow; Kevin Katz; Dennis T Ko; Allison J McGeer; Dayre McNally; David C Richardson; Laura C Rosella; Andrew Simor; Marek Smieja; George Zahariadis; Jonathan B Gubbay Journal: N Engl J Med Date: 2018-01-25 Impact factor: 91.245
Authors: Richard Kent Zimmerman; Mahlon Raymund; Janine E Janosky; Mary Patricia Nowalk; Michael J Fine Journal: Vaccine Date: 2003-03-28 Impact factor: 3.641
Authors: Edward A Belongia; Maria E Sundaram; David L McClure; Jennifer K Meece; Jill Ferdinands; Jeffrey J VanWormer Journal: Vaccine Date: 2014-06-21 Impact factor: 3.641
Authors: Feng Liu; F Liaini Gross; Stacie N Jefferson; Crystal Holiday; Yaohui Bai; Li Wang; Bin Zhou; Min Z Levine Journal: J Clin Invest Date: 2021-04-15 Impact factor: 14.808
Authors: Krissy K Moehling; Richard K Zimmerman; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Judith M Martin; John F Alcorn; Michael Susick; Ashley Burroughs; Crystal Holiday; Brendan Flannery; Min Z Levine Journal: Vaccine Date: 2020-06-21 Impact factor: 3.641
Authors: Carlos G Grijalva; Leora R Feldstein; H Keipp Talbot; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Jonathan D Casey; Heidi L Erickson; Matthew C Exline; D Clark Files; Kevin W Gibbs; Adit A Ginde; Michelle N Gong; Natasha Halasa; Akram Khan; Christopher J Lindsell; Samuel K Nwosu; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay S Steingrub; William B Stubblefield; Mark W Tenforde; Manish M Patel; Wesley H Self Journal: Clin Infect Dis Date: 2021-10-20 Impact factor: 9.079
Authors: Jill M Ferdinands; Manjusha Gaglani; Shekhar Ghamande; Emily T Martin; Donald Middleton; Arnold S Monto; Fernanda Silveira; Helen K Talbot; Richard Zimmerman; Emily R Smith; Manish Patel Journal: J Infect Dis Date: 2021-07-02 Impact factor: 5.226
Authors: Siva H Yedlapati; Safi U Khan; Swapna Talluri; Ahmed N Lone; Muhammad Zia Khan; Muhammad Shahzeb Khan; Ann M Navar; Martha Gulati; Heather Johnson; Seth Baum; Erin D Michos Journal: J Am Heart Assoc Date: 2021-03-13 Impact factor: 5.501
Authors: C Joaquín Cáceres; Stivalis Cardenas-Garcia; Aarti Jain; L Claire Gay; Silvia Carnaccini; Brittany Seibert; Lucas M Ferreri; Ginger Geiger; Algimantas Jasinskas; Rie Nakajima; Daniela S Rajao; Irina Isakova-Sivak; Larisa Rudenko; Amy L Vincent; D Huw Davies; Daniel R Perez Journal: Vaccines (Basel) Date: 2021-06-27
Authors: Constance E Ogokeh; Angela P Campbell; Leora R Feldstein; Geoffrey A Weinberg; Mary A Staat; Monica M McNeal; Rangaraj Selvarangan; Natasha B Halasa; Janet A Englund; Julie A Boom; Parvin H Azimi; Peter G Szilagyi; Christopher J Harrison; John V Williams; Eileen J Klein; Laura S Stewart; Leila C Sahni; Monica N Singer; Joana Y Lively; Daniel C Payne; Manish Patel Journal: J Pediatric Infect Dis Soc Date: 2021-04-30 Impact factor: 5.235
Authors: Shruti K Gohil; Keith Olenslager; Kathleen A Quan; Cyrus K Dastur; Nasim Afsar; Wayne Chang; Susan S Huang Journal: JAMA Netw Open Date: 2021-07-01